Biogen Appoints Catherine Steele Senior Vice President of Corporate Affairs
June 28 2017 - 7:30AM
Business Wire
Industry leader brings deep experience in
communications, patient advocacy and government policy
Biogen (NASDAQ: BIIB) announced today the appointment of
Catherine Steele as Senior Vice President of Corporate Affairs,
effective July 17.
Ms. Steele, who brings more than 25 years of public affairs
experience to Biogen, will lead the company’s corporate, product,
and internal communications as well government affairs and patient
advocacy efforts.
“Catherine is joining us at an exciting time in the evolution of
Biogen,” said Chief Executive Officer Michel Vounatsos. “As we
strengthen our pipeline, reaffirm our commitment to neuroscience
and look to enter new therapeutic areas and markets globally,
Catherine will play a crucial role in helping align our business
with key public and patient audiences and establish Biogen with new
stakeholders globally.”
Ms. Steele most recently served as Global Head, Communications
and Patient Relations at Novartis Pharmaceuticals, where she was
responsible for corporate reputation and helping drive external,
internal and executive communication strategies. She also led the
company’s social media and patient relations activities. Her career
in the biopharma industry began at Roche, where she spent more than
a decade in global communications and policy leadership roles.
"I am privileged to join Biogen, a respected and recognized
pioneer in neuroscience," said Ms. Steele. "I look forward to
building upon that legacy and being part of this company whose
commitment to patients, families and society affected by
neurological diseases is unwavering."
Ms. Steele holds dual undergraduate degrees in French and
political science from the University of New Brunswick and a Master
of Arts degree in political science from Carleton University.
About BiogenThrough cutting-edge science and medicine,
Biogen discovers, develops and delivers worldwide innovative
therapies for people living with serious neurological and
neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in
biotechnology, and today the company has the leading portfolio of
medicines to treat multiple sclerosis; has introduced the first and
only approved treatment for spinal muscular atrophy; and is at the
forefront of neurology research for conditions including
Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral
sclerosis. Biogen also manufactures and commercializes biosimilars
of advanced biologics. For more information, please visit
www.biogen.com. Follow us on social media – Twitter, LinkedIn,
Facebook, YouTube.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170628005103/en/
BiogenMEDIA CONTACT:Matt Fearer, +1 781-464
3260public.affairs@biogen.comorINVESTOR CONTACT:Matt Calistri,
+1-781-464-2442IR@biogen.com
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Apr 2023 to Apr 2024